Purpose: Acute myeloid leukemia (AML) is characterized by multiple somatically acquired mutations that affect genes of different functional categories. It has been well established in myelodysplastic syndrome (MDS) that the cumulative number of
Search Results
Zin W. Myint, Rani Jayswal, Ranjana Arora, Gregory P. Monohan, Amit Goldberg, Roger Fleischman, Roger Herzig, Hayder Saeed, Gerhard C. Hildebrandt, and Reshma Ramlal
The incidence of leukemia, along with its precursor, myelodysplasia, appears to be rising, particularly in the population over age 60. Recently an expanded panel of clinicians from the NCCN member institutions joined to update guidelines for the treatment of acute myeloid leukemia. Although there are some areas in which clinical trials have led to significant improvements in treatment, for the most part, recent trials have only served to highlight the continued need for innovative strategies to overcome this disease. These guidelines focus on outlining reasonable treatment options based on the information available.
For the most recent version of the guidelines, please visit NCCN.org
Roswell Park Cancer Institute
Approximately 11,960 people will be diagnosed with acute myeloid leukemia (AML) in 2005, and 9,000 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Equally disturbing is the increasing incidence of treatment-related myelodysplasia and leukemia in survivors of tumors of childhood and young adulthood such as Hodgkin's disease, sarcomas, breast and testicular cancers, and lymphomas. Recent large clinical trials have highlighted the need for new, innovative strategies because outcomes for AML patients, particularly older patients, have not substantially changed in the past 3 decades.
For the most recent version of the guidelines, please visit NCCN.org
Rafael Bejar
, for those with higher-risk MDS that evolves into acute myeloid leukemia (AML), overall survival (OS) is significantly reduced. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Rafael Bejar, MD, PhD, Associate Professor, UC San Diego Moores
Olga Frankfurt and Martin S. Tallman
, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . The International Acute Myeloid Leukemia Study Group . Blood 1997 ; 90 : 4710 – 4718
Jeffrey E. Lancet and Sergio Giralt
The authors have received research funding from Pharmion and are consultants for MGI Pharma. References 1. Surveillance, Epidemiology, and End Results (SEER) Program . Acute myeloid leukemia incidence for 2000-2004 . National
Gary H. Lyman and David C. Dale
) than control patients who did not receive prophylaxis. Cancer chemotherapeutic agents are associated with an increased risk of acute myeloid leukemia (AML). 6 , 7 Several common chemotherapeutic agents are considered to be leukemogenic 8 – 13
Juliana E. Hidalgo-López, Rashmi Kanagal-Shamanna, L. Jeffrey Medeiros, Zeev Estrov, C. Cameron Yin, Srdan Verstovsek, Sergej Konoplev, Jeffrey L. Jorgensen, Mohammad M. Mohammad, Roberto N. Miranda, Chong Zhao, John Lee, Zhuang Zuo, and Carlos E. Bueso-Ramos
Driver gene mutation status has been incorporated into the classification and prognostic assessment of patients with acute myeloid leukemia (AML) and, in some cases, these data are used for treatment decisions. 1 JAK2 is a nonreceptor tyrosine
Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, and Pankit Vachhani
BACKGROUND : Venetoclax in combination with azacitidine or decitabine(HMA+Ven)is the standard-of-care treatment for older adults(≥75 years) or those with comorbidities precluding intensive induction therapy in newly diagnosed acute myeloid
Quenton Rashawn Bubb, Corey Cheung, Gabriel Eduardo Seir,, Leah Swartzrock, Rebecca Richards, Crystal Mackall, and Agnieszka Czechowicz
Acute myeloid leukemia (AML) is a frequent subtype of cancer that affects thousands of children and adults worldwide. Current treatments generally consist of harsh, conventional chemotherapy and/or hematopoietic stem cell transplantation (HSCT
